首页> 美国卫生研究院文献>Frontiers in Chemistry >Radiochemical and biological assessments of a PSMA-IS cold kit for fast and inexpensive 99mTc-labeling for SPECT imaging and radioguided surgery in prostate cancer
【2h】

Radiochemical and biological assessments of a PSMA-IS cold kit for fast and inexpensive 99mTc-labeling for SPECT imaging and radioguided surgery in prostate cancer

机译:PSMA-IS 冷试剂盒的放射化学和生物学评估用于快速、廉价的 99mTc 标记用于前列腺癌的 SPECT 成像和放射引导手术

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The expression of prostate-specific membrane antigen (PSMA) is upregulated in prostate cancer (PCa) cells and PSMA-ligands have been radiolabeled and used as radiopharmaceuticals for targeted radionuclide therapy (TRT), single photon emission computed tomography (SPECT) or positron emission tomography (PET) molecular imaging, and radioguided surgery in PCa patients. Herein, we aimed at radiolabeling the PSMA-I&S cold kit with 99mTc, resulting in a radiopharmaceutical with high radiochemical yield (RCY) and stability for SPECT imaging and radioguided surgery in PCa malignancies. Various pre-clinical assays were conducted to evaluate the [99mTc]Tc-PSMA-I&S obtained by the cold kit. These assays included assessments of RCY, radiochemical stability in saline, lipophilicity, serum protein binding (SPB), affinity for LNCaP-PCa cells (binding and internalization studies), and ex vivo biodistribution profile in naive and LNCaP-PCa-bearing mice. The radiopharmaceutical was obtained with good RCY (92.05% ± 2.20%) and remained stable for 6 h. The lipophilicity was determined to be −2.41 ± 0.06, while the SPB was ∼97%. The binding percentages to LNCaP cells were 9.41% ± 0.57% (1 h) and 10.45% ± 0.45% (4 h), with 63.12 ± 0.93 (1 h) and 65.72% ± 1.28% (4 h) of the bound material being internalized. Blocking assays, employing an excess of unlabeled PSMA-I&S, resulted in a reduction in the binding percentage by 2.6 times. The ex vivo biodistribution profile confirmed high accumulation of [99mTc]Tc-PSMA-I&S in the tumor and the tumor-to-contralateral muscle ratio was ∼6.5. In conclusion, [99mTc]Tc-PSMA-I&S was successfully obtained by radiolabeling the cold kit using freshly eluted [99mTc]NaTcO4, exhibiting good RCY and radiochemical stability. The preclinical assays demonstrated that the radiopharmaceutical shows favorable characteristics for SPECT imaging and radioguided surgery in PCa patients.
机译:前列腺特异性膜抗原 (PSMA) 的表达在前列腺癌 (PCa) 细胞中上调,PSMA 配体已被放射性标记并用作靶向放射性核素治疗 (TRT)、单光子发射计算机断层扫描 (SPECT) 或正电子发射断层扫描 (PET) 分子成像的放射性药物,以及 PCa 患者的放射引导手术。在此,我们旨在用 99mTc 对 PSMA-I&S 冷试剂盒进行放射性标记,从而产生具有高放射化学产率 (RCY) 和稳定性的放射性药物,用于 PCa 恶性肿瘤的 SPECT 成像和放射引导手术。进行各种临床前测定以评估冷试剂盒获得的 [99mTc]Tc-PSMA-I&S。这些测定包括评估 RCY、盐水中放射化学稳定性、亲脂性、血清蛋白结合 (SPB)、对 LNCaP-PCa 细胞的亲和力(结合和内化研究)以及幼稚和携带 LNCaP-PCa 的小鼠的离体生物分布谱。放射性药物以良好的 RCY (92.05% ± 2.20%) 获得,并保持稳定 6 h。亲脂性测定为 -2.41 ± 0.06,而 SPB 约为 ∼97%。与 LNCaP 细胞的结合百分比分别为 9.41% ± 0.57% (1 h) 和 10.45% ± 0.45% (4 h),其中 63.12 ± 0.93 (1 h) 和 65.72% ± 1.28% (4 h) 的结合材料被内化。使用过量的未标记 PSMA-I&S 的封闭测定导致结合百分比降低 2.6 倍。离体生物分布谱证实 [99mTc] Tc-PSMA-I&S 在肿瘤中高度积累,肿瘤与对侧肌肉的比例约为 ∼6.5。总之,通过使用新鲜洗脱的 [99mTc]NaTcO4 对冷试剂盒进行放射性标记,成功获得了 [99mTc]Tc-PSMA-I&S,表现出良好的 RCY 和放射化学稳定性。临床前测定表明,放射性药物显示出对 PCa 患者进行 SPECT 成像和放射引导手术的有利特性。

著录项

代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号